Phase 1 Liver Cancer Trial, Recruiting NCT06848465 Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Condition: Liver Cancer
Back to Liver Cancer

Phase 1 Liver Cancer Trial, Recruiting

NCT06848465
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 75 years old.
  • People whose colon or rectal cancer has been confirmed by tissue testing to be a specific type called MSS/pMMR adenocarcinoma.
  • People with rectal cancer where scans (MRI, CT, or rectal ultrasound) show the cancer has reached certain stages involving the bowel wall or nearby lymph nodes (T3-4Nx or TXN1-2) (confirm with trial site).
  • People whose cancer has spread to the liver at the same time as the original diagnosis, confirmed by imaging scans.
  • People who have not had any previous cancer treatment.
  • People who are generally well enough to carry out light activity and care for themselves, as measured by a standard health scale (ECOG score of 0 or 1).
  • People whose heart, liver, kidneys, and blood counts are all within acceptable ranges based on standard tests.
  • People who are willing to sign a consent form and follow the trial requirements.

Who may not be able to join:

  • People whose cancer has spread to parts of the body other than the liver.
  • People with a body mass index (BMI) below 18.5, or who have lost 10% or more of their body weight in the past 6 months.
  • People who have taken an experimental drug, are currently in another interventional clinical trial, or have received anti-tumour or live vaccines.
  • People with active or past autoimmune diseases, or a history of certain liver conditions including hepatitis B, hepatitis C, or liver cirrhosis.
  • People with a history of immune system problems, a positive HIV test, other immune deficiency conditions, or who have had an organ transplant or bone marrow transplant.
  • People who have had a significant heart condition within the past 6 months, such as heart failure, heart attack, severe chest pain, bypass surgery, or poor heart pump function.
  • People who currently have another active cancer, or who have had another cancer in the past 5 years (with some exceptions for certain minor skin cancers or very early-stage cancers — confirm with trial site).
  • People who are pregnant or breastfeeding.
  • People whom the trial doctors consider unsuitable for any medical or other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Chuan Chen, MD PhD, Daping Hospital, Army Medical University

Phone: 13883089634

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Registry
ClinicalTrials.gov
Start date
28 February 2025
Est. completion
30 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of treatment-emergent adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov